ライフサイエンスコーパス: doxycycline

1 ne Brugia malayi model of minocycline versus doxycycline.

2 ice, and the double-transgenic mice were fed doxycycline.

3 ound expression and increased sensitivity to doxycycline.

4 n, and 283 were randomly assigned to receive doxycycline.

5 ced number of dead worms were observed after doxycycline.

6 4, 5, or 6 weeks of daily 100 or 200 mg oral doxycycline.

7 filariae more rapidly than those achieved by doxycycline.

8 trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline.

9 ter treatment with topical steroids and oral doxycycline.

10 expression was then ablated by withdrawal of doxycycline.

11 tages of IV minocycline over tigecycline and doxycycline.

12 or absence of penicillin, ciprofloxacin, or doxycycline.

13 ncreases were attenuated by azithromycin and doxycycline.

14 TMP-SMX plus placebo and 315 to TMP-SMX plus doxycycline.

15 ints did not fit the susceptibility data for doxycycline.

16 xpressed, but can be modulated in vivo using doxycycline.

17 -B cell line in which PU.1 can be induced by doxycycline.

18 xpression of oncogenic K-RAS is regulated by doxycycline.

19 ) or onchocerciasis (Onchocerca volvulus) is doxycycline.

20 tients treated with the anti-Wolbachia drug, doxycycline.

21 A 35/1 ratio of 1 and doxycycline (1-Dox 35/1) kills drug susceptible A. bauma

22 Doxycycline (100 mg twice daily for 21 days) remains the

23 riority of azithromycin (1 g in one dose) to doxycycline (100 mg twice daily for 7 days).

24 In conclusion, doxycycline (100 mg/kg/day) had no effect on CAVD progre

25 etronidazole and amoxicillin in combination, doxycycline (2 mug/mL), and azithromycin (10 mug/mL) ove

26 Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0.5 mg/kg

27 Second, a double-blind randomization between doxycycline (200 mg/day, once daily) and placebo was per

28 stant, among which 51.4% were susceptible to doxycycline, 29.7% to clindamycin, and 21.6% to trimetho

29 corticosteroids (1-3 weeks), short course of doxycycline (3 weeks), or a leukotriene antagonist may b

30 IV doxycycline (3, 10, or 30 mg/kg) given during resuscitat

31 At EOT, fatigue severity was similar between doxycycline (40.8 [95% confidence interval {CI}, 37.3-44

32 included in the intention-to-treat analysis (doxycycline, 52; placebo, 52; CBT, 50).

33 The PED + LDD group was treated orally with doxycycline (6 mg/kg) for 21 days after the ligature was

34 ortetracycline (5), oxytetracycline (6), and doxycycline (7) were biotransformed by a marine-derived

35 For those starting doxycycline, 83 (74%) of 112 patients had three or fewer

36 clinical isolates were resistant in vitro to doxycycline, 98% were only intermediate in susceptibilit

37 ine depletes Wolbachia more effectively than doxycycline (99.51% vs. 90.35%) after 28 day 25 mg/Kg bi

38 ed in cell culture by the addition of 25 mum doxycycline (a broad spectrum MMP inhibitor).

39 We aimed to elucidate the effect of doxycycline, a matrix metalloproteinase inhibitor, on ca

40 Here, we evaluated the effect of doxycycline, a nonselective MMP inhibitor on CAVD progre

41 Indeed, treatment with doxycycline-a tetracycline derivative-disturbs mitochond

42 moter activated by topical administration of doxycycline achieved the same effect.

43 Doxycycline administration can turn off the transgene ex

44 yosin heavy chain (MHC) gene is inhibited by doxycycline administration.

45 The condition was milder in mice given doxycycline after age postnatal day 14 and did not devel

46 cin, azithromycin, rifampin, gentamicin, and doxycycline against 101 isolates of Rhodococcus equi wer

47 for testing of minocycline, tigecycline, and doxycycline against 107 carbapenem-resistant A. baumanni

48 the vectors and the insufficient efficacy of doxycycline against P. ovale.

49 compared to stimulation with either BMP2 or doxycycline alone.

50 Doxycycline also significantly reduced TOS and OSI level

51 The efficacy of oral doxycycline, amoxicillin, and cefuroxime axetil for trea

52 omycetemcomitans, were resistant in vitro to doxycycline, amoxicillin, metronidazole, or clindamycin,

53 mono- or dual therapy (with azithromycin or doxycycline), anal, vaginal, or urine samples were self-

54 2013, 132 patients were randomly assigned to doxycycline and 121 to prednisolone from 54 UK and seven

55 ier estimates were 16.1% for those receiving doxycycline and 16.5% for those receiving placebo; diffe

56 Twenty-one patients receiving doxycycline and 22 patients receiving placebo had electi

57 eeks were 18% (22 of 121) for those starting doxycycline and 36% (41 of 113) for prednisolone (mITT),

58 domized trials demonstrated poor efficacy of doxycycline and better, but declining, efficacy of singl

59 ates confirming synergy with Clarithromycin, Doxycycline and Clindamycin, combinations of which were

60 tor-initiated multicenter trials highlighted doxycycline and dapsone as valuable medications in the t

61 factor D testing and recommendations against doxycycline and hormonal therapy.

62 zelaic acid, and ivermectin, as well as oral doxycycline and isotretinoin, are associated with improv

63 The patient improved with prolonged doxycycline and rifabutin treatment.

64 Overall, our results suggest that doxycycline and rifamycin are general inhibitors of Cu(I

65 ormation at the monomer stage, we found that doxycycline and rifamycin SV exert their effect by bindi

66 We found that two molecules, doxycycline and rifamycin SV, can inhibit beta2m amyloid

67 ld type beta2-microglobulin fibrillogenesis, doxycycline and single domain antibodies (nanobodies).

68 Treatment with doxycycline and transfection with guide RNA (gRNA), dono

69 d 52.3% for minocycline, 21.5% and 18.7% for doxycycline, and 71% and 29.9% for tigecycline, respecti

70 broth were 77.6% for minocycline and 29% for doxycycline, and 92.5% of isolates had tigecycline MICs

71 pinpoint the binding sites of rifamycin SV, doxycycline, and another molecule, suramin, which binds

72 nd carbadox, heterogeneous susceptibility to doxycycline, and low susceptibility to lincomycin and ty

73 Symptoms resolved after treatment with doxycycline, and no chronic sequelae or symptoms were ob

74 ms when compared directly with tetracycline, doxycycline, and other broad-spectrum antimicrobial agen

75 well tolerated and commonly used antibiotic doxycycline as a potent inhibitor of M2-type polarizatio

76 basis for onchocerciasis control and confirm doxycycline as a potent macrofilaricidal therapy.

77 and pregnancy are obstacles to implementing doxycycline as a public health strategy.

78 moxicillin at 8 mg/L, clindamycin at 4 mg/L, doxycycline at 4 mg/L, and metronidazole at 16 mg/L, wit

79 ve IV boluses of normal saline (control) and doxycycline at 5 minutes of reoxygenation (n = 7/group).

80 ibitory response in the presence of the drug doxycycline at the single-cell level to reveal their het

81 Postresuscitation administration of doxycycline attenuates cardiac injury and improves funct

82 or the microglia antagonists minocycline and doxycycline augmented sympathetic responses to KA-induce

83 cterial counts were significantly reduced by doxycycline, azithromycin, and amoxicillin alone or in c

84 Systemic corticosteroids and oral doxycycline (both for 3 weeks) reduced polyp size compar

85 Earlier treatment with doxycycline can decrease morbidity and mortality from RM

86 sed a 161% increase, whereas minocycline and doxycycline caused a 225% and 215% increase, respectivel

87 In the presence of doxycycline, chloramphenicol, or G418, the Sec-containin

88 dorferi--to receive a 12-week oral course of doxycycline, clarithromycin plus hydroxychloroquine, or

89 e a small increased efficacy of up to 3% for doxycycline compared with azithromycin for the treatment

90 ingle TFs in each line could be induced in a doxycycline-controllable manner.

91 137 mouse ESC lines, each of which carried a doxycycline-controllable TF.

92 we show that expression of the tetracycline/doxycycline-controlled Tet-transactivator, while tolerat

93 Thus, doxycycline could be used to enhance current antiangioge

94 4 were randomized to azithromycin and 302 to doxycycline; CT, MG, TV, and UU-2 were detected in 24%,

95 Doxycycline (DC) is forbidden compound in laying hens.

96 Recognition of risk factors associated with doxycycline delay and fatal outcome, such as early gastr

97 Multiple factors increased the risk of doxycycline delay and fatal outcome, such as early sympt

98 line of mice that expresses an inducible and doxycycline-dependent GFP-GluN2A transgene specifically

99 ive reverse liquid-liquid microextraction of doxycycline (DOC) from chicken fat.

100 Long-term treatment with doxycycline does not reduce fatigue severity in QFS pati

101 These changes are observed with doxycycline doses that are widely used to regulate gene

102 sion of an expanded repeat in the brain upon doxycycline (dox) exposure (i.e. Tet-On mice).

103 l fibroblasts, expressing miR-449b through a doxycycline (dox) induced expression system were used as

104 Tat expression is induced by activation of a doxycycline (Dox) promotor, we tested the effects of Tat

105 bjective of the present study is to quantify doxycycline (DOX) release from beta-tricalcium phosphate

106 or protein transgenic mice were treated with doxycycline (dox) to suppress further amyloid precursor

107 whose LRP4 gene can be deleted in muscles by doxycycline (Dox) treatment.

108 tracycline (TC), chlortetracycline (CTC) and doxycycline (DOX), respectively.

109 onding characteristics to dentin of a unique doxycycline (DOX)-encapsulated halloysite nanotube (HNT)

110 We employed a doxycycline (DOX)-inducible CTSB expression system to se

111 Doxycycline (dox)-inducible lentiviral vectors containin

112 on in vivo can be controlled temporally with doxycycline (Dox).

113 out administration of post-surgical systemic doxycycline (DOXY) 12 and 24 months after therapy.

114 These polymer conjugates are based on doxycycline (doxy), already in phase II trials for Alzhe

115 nuated by 60% in individuals who were under doxycycline during acquisition.

116 Conjugation of doxycycline exhibited greater potential towards TTR fibr

117 Doxycycline exhibited the most prominent inhibition on g

118 Doxycycline exhibits superior PK in comparison to minocy

119 lenged doxycycline-exposed compared with non-doxycycline-exposed CC10-IL-15 bitransgenic mice.

120 tance, was diminished in allergen-challenged doxycycline-exposed compared with non-doxycycline-expose

121 Doxycycline-exposed, Aspergillus species extract-challen

122 These mice reacted to doxycycline exposure by spontaneous electrocorticography

123 underwent exfoliation that increased during doxycycline exposure.

124 receive TMP-SMX plus placebo or TMP-SMX plus doxycycline for 20 weeks (1:1; block size of ten, strati

125 optimal response and treated with 100 mg/day doxycycline for 6 weeks.

126 and prescription of a 14-day course of oral doxycycline for early neurologic Lyme disease in ambulat

127 Studies on the use of doxycycline for MALT lymphomas (137 patients) reported c

128 vely treat febrile illnesses and sepsis with doxycycline for suspected RMSF.

129 that TMP-SMX is not inferior to TMP-SMX plus doxycycline for the oral phase of melioidosis treatment,

130 nd side-effects of TMP-SMX with TMP-SMX plus doxycycline for the oral phase of melioidosis treatment.

131 ontrolled trials comparing azithromycin with doxycycline for the treatment of genital chlamydia with

132 hlamydia and about 7% increased efficacy for doxycycline for the treatment of symptomatic urethral in

133 mized trial comparing oral azithromycin with doxycycline for the treatment of urogenital chlamydia in

134 ocerca volvulus Wolbachia endosymbionts with doxycycline for these individuals with suboptimal respon

135 ampin represents an effective alternative to doxycycline for treatment of African tick bite fever in

136 e shown efficacy for a 10-day course of oral doxycycline for treatment of erythema migrans and for a

137 re evaluated in groups of mice that received doxycycline for varying periods from 0 to 40 weeks of ag

138 In contrast, mice treated with doxycycline from conception to 6 weeks had markedly less

139 i-chlorotetracycline, chlorotetracycline and doxycycline) from milk.

140 It was observed that 10% doxycycline gel had a good effect on bone regeneration r

141 lot), NAT (natrosol gel alone), and DOX (10% doxycycline gel).

142 hether a strategy of starting treatment with doxycycline gives acceptable short-term blister control

143 placebo group (-1.9 dB) and increased in the doxycycline group (+1.8 dB) (P = .02).

144 plus placebo group than in the TMP-SMX plus doxycycline group (122 [39%] vs 167 [53%]).

145 A higher mean FDP foveal sensitivity in the doxycycline group compared with the placebo group was de

146 oup and 21 patients (7%) in the TMP-SMX plus doxycycline group developed culture-confirmed recurrent

147 fference of 0.2 [95% CI, -2.4 to 2.8] in the doxycycline group vs. the placebo group and a difference

148 nfidence interval [CI], 33.5 to 36.5) in the doxycycline group, 35.6 (95% CI, 34.2 to 37.1) in the cl

149 ention-to-treat analysis (86 patients in the doxycycline group, 96 in the clarithromycin-hydroxychlor

150 There were no treatment failures in the doxycycline group.

151 tis and placebo treatment; and 3) ligature + doxycycline group: ligature-induced periodontitis and SD

152 ystemic arterial pressure ratio was lower in doxycycline groups, with reduced levels of markers of my

153 Despite therapeutic blood levels, doxycycline had no significant effect on MMP activation,

154 In the presence of doxycycline, HD10.6 cells mature to exhibit neuronal mor

155 Doxycycline helps to prevent periodontal tissue breakdow

156 significant association between the cost of doxycycline hyclate and market concentration as assessed

157 The percentage of prescriptions for doxycycline hyclate decreased by 1.9% from 2011 to 2013.

158 This dramatic increase in the cost of doxycycline hyclate is not easily explained using the fr

159 Between 2011 and 2013, the mean cost of doxycycline hyclate prescriptions increased from $7.16 t

160 Therapy with doxycycline hydrochloride and minocycline hydrochloride

161 Doxycycline improved cardiac and stroke volume index wit

162 e 1 displays strong synergistic effects with doxycycline in a wide range of concentrations.

163 tor system was observed with the addition of doxycycline in drinking water, confirming that the cysta

164 expected to be 1.7 fold more effective than doxycycline in man despite lower exposure in our infecti

165 be too small to detect a treatment effect of doxycycline in patients with mild to moderate NPDR.

166 Combined treatment of BMP2 and doxycycline in PDL cells counteracts the osteogenic medi

167 ession (17.7- to 73-fold) in the presence of doxycycline in several endothelial cell lines, but witho

168 gate the effects of the local application of doxycycline in the form of natrosol-based gel on bone re

169 radation was suppressed by the MMP inhibitor doxycycline in vitro.

170 trary to expected results, combined BMP2 and doxycycline induced a statistically significant (P <0.00

171 e significantly reduced or absent in TPA- or doxycycline-induced cells expressing lytic KSHV proteins

172 oss of folates was not measurable from these doxycycline-induced cells or from parental CHO cells ove

173 Doxycycline-induced expression of FIP1C in the MMTV-ErbB

174 we use a novel transgenic mouse model, where doxycycline-induced overexpression of vascular endotheli

175 letion in MCF10A cells engineered to express doxycycline-induced shHOXA5 slowed transition of cells f

176 Here, we used a doxycycline inducible system with ChIP-seq to assess how

177 ablished HEK293 cell lines stably expressing doxycycline-inducible (Tet-on) reference APOL1 G0 or the

178 Here we use a doxycycline-inducible adipocyte-specific endotrophin ove

179 In the study, we took advantage of doxycycline-inducible and astrocyte-specific HIV-1 Tat t

180 We developed a protocol based on a doxycycline-inducible Cas9 transgene carried on a piggyB

181 enges, we first developed a highly efficient doxycycline-inducible Cas9-EGFP vector.

182 These observations were further validated in doxycycline-inducible CC10-IL-15 bitransgenic mice.

183 ed Gfi-1b allele in combination with a novel doxycycline-inducible Cre transgene that efficiently med

184 CRISPRi, in which a doxycycline-inducible deactivated Cas9 is fused to a KRA

185 fts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expres

186 ntiviral-based DUX4 expression in myoblasts, doxycycline-inducible DUX4 in myoblasts, and differentia

187 igenesis, we engineered transgenic mice with doxycycline-inducible expression of Nup88.

188 this hypothesis, we generated cell lines for doxycycline-inducible expression of short hairpin RNAs (

189 ch signaling within adult myocardium using a doxycycline-inducible genetic system (inducible Notch in

190 could be readily transduced to NRVMs by the doxycycline-inducible lentiviral system; however, high-l

191 The present work aimed to examine how the doxycycline-inducible lentiviral-mediated ChR2 expressio

192 ycle induction in TREX-BCBL-1 cells with the doxycycline-inducible lytic cycle switch replication and

193 Here, we show that the doxycycline-inducible parietal epithelial cell (PEC)-spe

194 iption of lentiviral vector sequences from a doxycycline-inducible promoter eliminated superinduction

195 ic isoforms of human FPGS under control of a doxycycline-inducible promoter in the AUXB1 cell line.

196 Here, we introduced a doxycycline-inducible promoter system (comprised of a te

197 colonized tumors of patients, we discuss the doxycycline-inducible promoter system adjustment and fur

198 address this, we developed a cell line with doxycycline-inducible RTA expression and applied stable

199 ed several single, endothelial-specific, and doxycycline-inducible self-inactivating (SIN) lentiviral

200 y means of CRISPR/Cas9-mediated knockout and doxycycline-inducible short hairpin RNA-mediated knockdo

201 KRAS knockdown by a doxycycline-inducible shRNA attenuated BCL-XL expression

202 ifically, we introduced a podocyte-specific, doxycycline-inducible transactivator into a murine embry

203 n of a claudin-1 transgenic mouse model with doxycycline-inducible transgene expression specifically

204 We used male and female mice of a doxycycline-inducible transgenic line to induce expressi

205 es of the most common U2AF1 mutation using a doxycycline-inducible transgenic mouse model.

206 Overexpression of APOL1 by doxycycline induction in HEK293 Tet-on G1 and G2 cells l

207 to generate global gene expression data with doxycycline induction.

208 Furthermore, doxycycline inhibited M2-type macrophage polarization an

209 Doxycycline inhibited, in a dose-dependent manner, M2-ty

210 Doxycycline inhibits formation and progression of abdomi

211 dence indicates that a 10-day course of oral doxycycline is effective for HGA and that a 7- to 10-day

212 INTERPRETATION: Starting patients on doxycycline is non-inferior to standard treatment with o

213 Azithromycin or doxycycline is recommended for nongonococcal urethritis

214 The target of doxycycline is the essential endosymbiont, Wolbachia.

215 hema migrans for no longer than 10 days when doxycycline is used and prescription of a 14-day course

216 Subantibiotic doses of doxycycline (low-dose doxycycline [LDD]) have been widely used in periodontal

217 achyspira murdochii to tiamulin, valnemulin, doxycycline, lincomycin, and tylosin by broth microdilut

218 ICs to amoxicillin, cefotaxime, ceftriaxone, doxycycline, linezolid, meropenem, penicillin, rifampin,

219 Subantibiotic doses of doxycycline (low-dose doxycycline [LDD]) have been widel

220 Oral doxycycline may be a promising therapeutic strategy targ

221 ocular adnexal MALT lymphomas where upfront doxycycline may be a reasonable and effective initial tr

222 Our findings suggest that azithromycin and doxycycline may be effective adjuvants to standard antia

223 However, doxycycline-mediated repression of exogenous DNMT1* init

224 8 microg/mL) displayed greater activity than doxycycline (MIC(50/90): 2/>8 microg/mL) and tetracyclin

225 ine MICs of >/= 4 mug/ml and in >/= 90% with doxycycline MICs of >/= 1.

226 MICs versus corresponding zone diameters and doxycycline MICs versus zones were prepared, and analysi

227 ch investigations that evaluated the role of doxycycline, minocycline, and azithromycin in OSD among

228 omparable cost increase was not observed for doxycycline monohydrate or minocycline.

229 Patients were randomized to receive 50 mg of doxycycline monohydrate or placebo daily for 24 months.

230 t Diabetic Retinopathy Study level 20-43) to doxycycline monohydrate, 50 mg/d, or daily placebo for 2

231 Daily dose of 100 mg of doxycycline (n = 144) or placebo (n = 142) for 18 months

232 und a pooled efficacy difference in favor of doxycycline of 1.5% (95% confidence interval [CI], -.1%

233 ters are pertinent to the prospects of using doxycycline on a "test and treat" basis for onchocercias

234 zithromycin, clindamycin, ciprofloxacin, and doxycycline on blood-supplemented Mueller-Hinton agar an

235 After 6 months, we evaluated the effect of doxycycline on CAVD progression by echocardiography, MMP

236 tions may relate to a differential effect of doxycycline on different stages of diabetic retinal dysf

237 efficacy of either long-term treatment with doxycycline or cognitive-behavioral therapy (CBT) in red

238 l cells were then treated with azithromycin, doxycycline, or control medium to determine whether anti

239 ty acid supplements (72/104, 69 %), low-dose doxycycline (oral; 61/100, 61 %), and flaxseed supplemen

240 r and cutaneous rosacea unresponsive to oral doxycycline, oral isotretinoin, and topical tacrolimus.

241 In this study, the efficacy of antibiotics (doxycycline, oxacillin and rifampicin) in preventing Sta

242 and 3) rats with PED that were treated with doxycycline (PED + LDD).

243 opical cyclosporine, topical vitamin A, oral doxycycline, punctal occlusion, or a combination thereof

244 e therapeutic efficacy and compare different doxycycline regimens, evaluated at different times after

245 eCP2 repression by a cardiomyocyte-specific, doxycycline-regulatable transgenic mouse model aggravate

246 ngineered ES cells from WT mice to express a doxycycline-regulated (dox-regulated) shRNA that targets

247 e generated a transgenic mouse with enhanced doxycycline-regulated A1R expression, specifically in fo

248 r dystrophy mouse model with muscle-specific doxycycline-regulated DUX4 expression.

249 and contraction using novel reporters and a doxycycline-regulated expression system for RPB1 In effo

250 An endothelial-specific doxycycline-regulated mouse model for the expression of

251 We found that transgene (Tg) induction by doxycycline removal at weaning led to motor abnormalitie

252 Using a regulatable (doxycycline-repressible) gene expression system, we foun

253 2.9% for minocycline and 34.6% and 34.6% for doxycycline, respectively, and rates of MICs of </=2 mug

254 g 1147 and 912 patients for azithromycin and doxycycline, respectively.

255 ome this immediate lethality, we generated a doxycycline-responsive tTA-DNMT1* rescue line and readil

256 The patient was treated with doxycycline, rifampicin, and gentamicin, and underwent s

257 Subantimicrobial dose doxycycline (SDD) has been used as an adjunct in periodo

258 DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expressi

259 the Nkx2.5+ cardiomyoblasts, we generated a doxycycline suppressible Cre transgenic mouse under the

260 c (Tg) mice with forebrain Camk2a-controlled doxycycline-suppressible expression of a TDP-43 CTF (ami

261 nd epilepsy, we engineered dTg-211 mice with doxycycline-suppressible forebrain overexpression of miR

262 be repressed by steatotic drugs (valproate, doxycycline, tetracycline, and cyclosporin A) in culture

263 The estimated efficacy of doxycycline (the maximum proportional reduction in the p

264 h macrolides or fluoroquinolones rather than doxycycline, the preferred chlamydia treatment.

265 Four to six weeks doxycycline therapy achieves >90% depletion of Wolbachia

266 ns of HGA but who have a delayed response to doxycycline therapy or negative confirmatory test result

267 entrations ranged from 5.65-596microg/kg for doxycycline to 0.89-134microg/kg for enrofloxacin.

268 Administration of doxycycline to Clara cell secretory protein-reverse tetr

269 Strategies can now be developed that include doxycycline to control onchocerciasis in areas where inf

270 Feeding mice doxycycline to induce Zap70 expression resulted in repop

271 Doxycycline to treat early and late latent syphilis is a

272 (12 to 13 months after tick inoculation) in doxycycline-treated (28 days; 5 mg/kg, oral, twice daily

273 RNA sequencing demonstrated in doxycycline-treated dTg-211 cortices overrepresentation

274 Wolbachia positive, whereas only 5.1% in the doxycycline-treated group contained bacteria.

275 ryogenesis, none of the nodules removed from doxycycline-treated patients contained microfilariae, an

276 of myocardial injury and oxidative stress in doxycycline-treated piglets compared with controls.

277 volume index with no chronotropic effect in doxycycline-treated piglets compared with controls.

278 Doxycycline-treated piglets had lower myocardial matrix

279 Clinical trials have shown that doxycycline treatment eliminates Wolbachia, causing long

280 Three and 12 months after doxycycline treatment, patients took part in standard IV

281 in hPSCs is tightly regulated in response to doxycycline treatment.

282 the efficacy of 1 g azithromycin with 100 mg doxycycline twice daily (7 days) for the treatment of ur

283 acebo (37.8 [95% CI, 34.3-41.2]; difference, doxycycline vs placebo, -3.0 [97.5% CI, -8.7 to 2.6]; P

284 of azithromycin was 97%, and the efficacy of doxycycline was 100%.

285 All patients recovered completely when doxycycline was administered.

286 The presence of enrofloxacin and doxycycline was confirmed in real egg albumen samples.

287 Doxycycline was initiated significantly later in fatal c

288 st Pseudomonas aeruginosa when combined with doxycycline was precisely evaluated utilizing biolumines

289 Then, we found that doxycycline was the most effective compound, with import

290 e amyloid inhibitors (i.e., rifamycin SV and doxycycline), we demonstrate that covalent labeling and

291 ongoing international clinical trials using doxycycline, we studied the efficacy of cyclines against

292 s of enoxacin, bis-enoxacin, alendronate, or doxycycline were administered for 6 weeks after 6 weeks

293 s should have a low threshold for initiating doxycycline whenever treating febrile or potentially sep

294 months, half of the animals was treated with doxycycline, while the others continued WD alone.

295 76N beta2-microglobulin fibrillogenesis than doxycycline with complete abrogation of fibril formation

296 ibility testing interpretive breakpoints for doxycycline with Streptococcus pneumoniae and to reasses

297 By 7 days following doxycycline withdrawal, gene expression, cell proliferat

298 modified mice with lung-specific inducible (doxycycline) Wnt-1 expression (CCSP-rtTA x tetO-Wnt1), t

299 We assumed that doxycycline would be 25% less effective than corticoster

300 rapidly controlled following treatment with doxycycline, yet three years after initiation of the tre